The confluence of stereotactic ablative radiotherapy and tumor immunology.
about
PD-1/PD-L1 blockades in non-small-cell lung cancer therapyStereotactic radiosurgery (SRS) in the modern management of patients with brain metastasesRadiobiological mechanisms of stereotactic body radiation therapy and stereotactic radiation surgeryNovel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapiesThe potential of radiotherapy to enhance the efficacy of renal cell carcinoma therapyThe impact of the myeloid response to radiation therapyCheckpoint inhibitors in lung cancer: latest developments and clinical potentialA current perspective on stereotactic body radiation therapy for pancreatic cancerImmunotherapy and radiation therapy for malignant pleural mesothelioma.Neoadjuvant radiotherapy of early-stage breast cancer and long-term disease-free survival.Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer.Oligometastases in prostate cancer: restaging stage IV cancers and new radiotherapy options.Cancer-associated fibroblasts from lung tumors maintain their immunosuppressive abilities after high-dose irradiation.Unsanctifying the sanctuary: challenges and opportunities with brain metastases.Proton irradiation impacts age-driven modulations of cancer progression influenced by immune system transcriptome modifications from splenic tissueRadiation takes its TollClinical opportunities in combining immunotherapy with radiation therapy.A randomised phase II trial of Stereotactic Ablative Fractionated radiotherapy versus Radiosurgery for Oligometastatic Neoplasia to the lung (TROG 13.01 SAFRON II)Feasibility study of DCs/CIKs combined with thoracic radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancerOpportunities for Radiosensitization in the Stereotactic Body Radiation Therapy (SBRT) EraCellular immunotherapy for soft tissue sarcomas.Dendritic cell immunotherapy in soft tissue sarcoma.Radiobiological basis of SBRT and SRS.Advances in local and ablative treatment of oligometastasis in prostate cancer.Stereotactic body radiation therapy in pancreatic cancer: the new frontier.The Rationale for Optimal Combination Therapy With Sipuleucel-T for Patients With Castration-resistant Prostate Cancer.Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies.Increasing radiation dose improves immunotherapy outcome and prolongation of tumor dormancy in a subgroup of mice treated for advanced intracerebral melanoma.From chemotherapy to target therapies associated with radiation in the treatment of NSCLC: a durable marriage?Concurrent dendritic cell vaccine and strontium-89 radiation therapy in the management of multiple bone metastases.Personalized peptide vaccines and their relation to other therapies in urological cancer.Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach.Serial assessment of lymphocytes and apoptosis in the prostate during coordinated intraprostatic dendritic cell injection and radiotherapy.From bench to bedside: bringing immunotherapy into the clinic.Local High-Dose Radiotherapy Induces Systemic Immunomodulating Effects of Potential Therapeutic Relevance in Oligometastatic Breast Cancer.Multimodality Treatment of Advanced Non-small Cell Lung Cancer: Where are we with the Evidence?Abscopal effect of metastatic pancreatic cancer after local radiotherapy and granulocyte-macrophage colony-stimulating factor therapy.Developing rational combinations of immune checkpoint inhibitors and radiation therapy for gastrointestinal cancers.Personal perspectives on the evolution of radiation therapy and future outlook for SRS.Treatment of Oligometastatic Hormone-Sensitive Prostate Cancer: A Comprehensive Review.
P2860
Q26765024-57560471-7FD7-4477-9BD9-6134C0F7EDE8Q26768667-F3A1F167-9B74-4CF3-9A99-CF33BB50ACCFQ26772259-58B28C3C-1056-440D-B98F-C14AAD05B573Q26775388-6F933B3E-F4DD-4E72-AE64-2E53A50DAF93Q26783291-0124A60F-2814-4454-9245-08CEBC35FA11Q26851643-0A9E89A4-7D94-4F63-91ED-713107E79017Q28076467-71D18A31-CA30-41EB-AD85-AC8DE0CA2DC6Q28077111-C53B1D7F-5CB8-4CD9-A4BC-4DA259529A74Q33645613-BF613D05-F11B-44A3-A388-55E7C7E0F5FDQ33859105-1F2DF247-FA97-434F-8D33-866CEADBE40EQ34321844-C81AA5D9-87EB-48E6-A58F-E46882FE6A82Q34748629-19814D16-9815-453A-8D30-F23C2FBAD63FQ35598951-F0ED4C20-287F-4A57-AA17-45E5CB3BDAD7Q35788631-8183EAD8-8579-481F-9101-C586A29C9EE3Q36078666-3CEA8798-9110-4A7C-9A36-665A064AB7A0Q36083353-B5E10856-EE4E-44A6-B32F-1B04C9CAD18FQ36449873-2CFF8F54-57C5-4191-B11C-EE7891A19FD3Q36651935-A0581945-AA67-4C4A-B895-BF56542E260CQ36820371-9D3C63C9-AB1E-4F35-8CFD-4B0325C2FFE9Q37118895-3D3E6374-484B-4D12-8879-06BDE5F284A2Q37991779-23434444-B1C1-4ADF-BDA4-BE08DAB4BAC2Q38059515-B9711D68-7E28-4990-9316-DD0E2A93A1CDQ38226118-DD35B1E6-2688-4748-9F40-7B7483D22D05Q38243113-A43F074B-FF58-4CE2-AB4A-E4444059E9F2Q38245676-C259E4B5-A82B-40E9-84AB-61EE9B47C5A2Q38261921-996934AB-FD34-4080-819D-3CA8954CCF08Q38670099-05885404-A541-47FA-967E-049AAED80DE3Q38812183-39352224-FF4D-4A22-91A4-34E54932E128Q39041541-80881726-CCC3-4B17-8049-3C6511860EF2Q39206316-C82B644C-1890-449D-BC9F-1A2A65DCF770Q39340541-B1AC53D2-F0C4-4ABF-99DB-296DA8CDB0F7Q39385461-5342030A-E157-4CED-AF33-AF40416BA325Q39627913-299781E2-AA66-47BF-87AA-5B26784D3D2BQ45811888-AFD3B45B-0CBB-4DE2-B967-5FC3809D4A16Q47115510-DBE854CB-41ED-4422-92AB-2AA28DA8467DQ49773079-03BB9477-6084-4158-B1CD-644F38899645Q51108391-9D701496-F8F6-4FDD-BAD5-BCE25CB09400Q55292088-10509A03-9D4D-4137-A20E-2CEC6A02A100Q55317264-8C75D8F1-AADA-4E71-AFD7-355D7EEADB79Q55379783-23D25AEA-049B-4315-A501-5F4E4724CB42
P2860
The confluence of stereotactic ablative radiotherapy and tumor immunology.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
The confluence of stereotactic ablative radiotherapy and tumor immunology.
@en
The confluence of stereotactic ablative radiotherapy and tumor immunology.
@nl
type
label
The confluence of stereotactic ablative radiotherapy and tumor immunology.
@en
The confluence of stereotactic ablative radiotherapy and tumor immunology.
@nl
prefLabel
The confluence of stereotactic ablative radiotherapy and tumor immunology.
@en
The confluence of stereotactic ablative radiotherapy and tumor immunology.
@nl
P2093
P2860
P921
P356
P1476
The confluence of stereotactic ablative radiotherapy and tumor immunology.
@en
P2093
Constantine A Mantz
Dörthe Schaue
Robert Timmerman
Sarah E Hoffe
Steven Eric Finkelstein
William H McBride
P2860
P304
P356
10.1155/2011/439752
P5008
P577
2011-11-15T00:00:00Z